OS Therapies (NYSE:OSTX) Earns “Buy” Rating from D. Boral Capital

OS Therapies (NYSE:OSTX)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $20.00 target price on the stock. D. Boral Capital’s target price suggests a potential upside of 385.44% from the company’s current price.

Separately, Maxim Group began coverage on shares of OS Therapies in a report on Tuesday, November 26th. They set a “buy” rating and a $8.00 target price on the stock.

OS Therapies Price Performance

OS Therapies stock opened at $4.12 on Wednesday. OS Therapies has a fifty-two week low of $1.58 and a fifty-two week high of $7.00. The firm has a 50 day moving average of $3.29.

Institutional Investors Weigh In On OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC purchased a new stake in OS Therapies Inc (NYSE:OSTX) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.